Lotus Pharmaceutical Co., Ltd.
Research Lotus Pharmaceutical Co., Ltd. (1795.TW) on Bullrun: market cap TWD 48.23B, P/E 12.7, dividend yield 1.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1795.TW
- ExchangeTW
- CountryTaiwan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyTWD
- Market capTWD 48.23B
- P/E12.7
- Dividend yield1.6%
- Financial periodQ2 2026
- RevenueTWD 8.81B
- Net incomeTWD 642.25M
- Free cash flow-TWD 367.58M
- Gross margin53.7%
Valuation Snapshot
latest market cap is TWD 48.23B; P/E is 12.7; dividend yield is 1.6%.
Peer valuation comparison
Latest P/E is 12.73x versus a Healthcare sector median of 21.8x (41.6% below).
Latest dividend yield is 1.64% versus a Healthcare sector median of 2.4% (31.7% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 48.23B | 12.7 | 1.4% | 2.57 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 2.57 TWD, yield 1.6%.
About Lotus Pharmaceutical Co., Ltd.
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products;
ETFs that hold Lotus Pharmaceutical Co., Ltd.
US-listed ETFs
Lotus Pharmaceutical Co., Ltd. is held by 21 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares Core MSCI Emerging Markets ETF (IEMG) | 0.01% | 0.09% |
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | 0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| iShares Core MSCI Total International Stock ETF (IXUS) | <0.01% | 0.07% |
| Avantis Emerging Markets Equity ETF (AVEM) | 0.01% | 0.33% |
| State Street SPDR Portfolio Emerging Markets ETF (SPEM) | <0.01% | 0.07% |
| Vanguard FTSE All-World ex-US Small-Cap Index Fund ETF Shares (VSS) | 0.02% | 0.06% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Lotus Pharmaceutical Co., Ltd.'s market cap?
Lotus Pharmaceutical Co., Ltd.'s market capitalization is TWD 48.23B.
What is Lotus Pharmaceutical Co., Ltd.'s P/E ratio?
Lotus Pharmaceutical Co., Ltd.'s price-to-earnings (P/E) ratio is 12.7.
Does Lotus Pharmaceutical Co., Ltd. pay a dividend?
Lotus Pharmaceutical Co., Ltd. has a dividend yield of 1.6%.
What does Lotus Pharmaceutical Co., Ltd. do?
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity.